“Profile of sales and notifications of suspected adverse events related to hydroxychloroquine and chloroquine during the COVID-19 pandemic”, RSD, vol. 12, no. 2, p. e15112240021, Jan. 2023, doi: 10.33448/rsd-v12i2.40021.